Last reviewed · How we verify
NCT05864430
Effıcıency of Sexual and Reproductıve Health Educatıon
NA trial testing Face-to-face Training Group in Reproductive Health in 165 participants. Completed in 30 December 2022.
30 September 2022
Quick facts
| Lead sponsor | Marmara University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 165 |
| Start date | 15 May 2022 |
| Primary completion | 30 September 2022 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Face-to-face Training Group
- DataMatrix supported Face-to-face training group
- Online training group
Conditions studied
- Reproductive Health — all drugs for Reproductive Health →
- Sexual Health — all drugs for Sexual Health →
Sponsor
Marmara University
Who can join
Adults 18 to 49, any sex, with Reproductive Health or Sexual Health. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The youth period is a period when information and education are important. Reproductive and sexual health problems have an important place in aging health problems in youth (Gölbaşlı 2003). All over the world, STIs are most common in the 20-24 age group, followed by the 15-19 and 25-29 age groups. STIs are the most common disease in many countries, especially among young people between the ages of 15-29 (Topbaş et al. 2003). STIs, which are one of the factors that negatively affect public health; are infections transmitted from person to person through sexual contact. According to WHO estimates, approximately 350 million people suffer from curable STIs each year, and the incidence and prevalence of STIs among young people in developed and developing countries are increasing. Although young adults are generally at risk, STIs are most common in people aged 15-49. They have a very important place in terms of human health because they are frequently seen, difficult to diagnose, and cause serious complications when not treated. Incomplete and incorrect information among people who start sexual intercourse at an early age causes difficulties in the prevention of these diseases (Özalp et al. 2012). Having sexual intercourse at an early age, being polygamous, having special sexual preferences, being with or having sex with those who have paid for sexual intercourse, and not using condoms are among the risk factors for STIs (Siyez 2009). We can say that the age period in which STIs are common is parallel to sexual activity. In addition to various socio-demographic factors, it is likely that the most provoking issue in this period is the lack of knowledge of young people (Karaköse and Aydın 2011). In the STD guide published by the CDC, it is recommended to evaluate the people who constitute the risk group in the prevention of these diseases and to provide education and counseling (CDC, 2020). In this context, training to increase the level of knowledge and awareness of young people, who are one of the high-risk groups in society in terms of STD, is important in terms of reducing risky sexual behaviors, early diagnosis, and treatment. Based on all these reasons; It is aimed to evaluate the effectiveness of sexual and reproductive health education given to university students.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation of the Effectiveness of Sexual and Reproductive Health Education Given to University Students: A Randomized Controlled Trial.
Öz T, Arslan Tarus H, Ölmez Yalazı R, Demirci N. · · 2025 · PMID 40400558 · DOI 10.1080/19317611.2025.2486105
Verify or expand the search:
- PubMed search for NCT05864430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Reproductive Health
Currently open trials in the same condition.
- NCT06684613 — Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics · NA · recruiting
- NCT05910580 — Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years · NA · recruiting
- NCT07275671 — Microbiome and Premature Ovarian Insufficiency · recruiting
- NCT06936930 — Reproductive and Mental Health of Patients With Aplastic Anemia · recruiting
- NCT06945016 — Monitoring Nutritional Consequences of Obesity Treatment on Women's Health · recruiting
Other Marmara University trials
Trials by the same sponsor.
- NCT07533734 — The Effects of an Augmented Reality-Based Mirror Therapy System in Patients With Stroke · NA · not yet recruiting
- NCT07474181 — Simulation-Based Training for Urinary Catheterization Skills in Nursing Students · NA · not yet recruiting
- NCT07486349 — Shoulder Pericapsular Block Versus Interscalene Block in Arthroscopic Shoulder Surgery · NA · not yet recruiting
- NCT07468110 — Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke · recruiting
- NCT07468097 — The Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05864430 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marmara University
- Last refreshed: 18 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05864430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing